X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OTT166 (nesvategrast) is an investigational, patented, potent and selective RGD integrin inhibitor to regulate cellular responses to VEGF and other growth factors known to contribute to development and progression of diabetic retinopathy and other ocular diseases.
Lead Product(s): Nesvategrast
Therapeutic Area: Ophthalmology Product Name: OTT166
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2024
Details:
OTT166 (nesvategrast) is a novel small molecule, potential first-in-class selective RGD integrin inhibitor specifically engineered for ocular delivery. It is under phase 2 clinical development for the treatment of diabetic retinopathy.
Lead Product(s): Nesvategrast
Therapeutic Area: Ophthalmology Product Name: OTT166
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
OTT166 is an investigational, novel, potent and selective small molecule RGD integrin inhibitor to allow it to distribute to the retina in high concentrations after topical (eye drop) administration to the eye.
Lead Product(s): OTT166
Therapeutic Area: Ophthalmology Product Name: OTT166
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2023
Details:
OTT166,an investigational, novel, patented, potent and selective small molecule RGD integrin inhibitor demonstrated ability to reach retina from eye drop application and produced robust biological activity signal in patients.
Lead Product(s): OTT166
Therapeutic Area: Ophthalmology Product Name: OTT166
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
OTT166 has demonstrated tolerability and promising evidence of biological activity in patients in Phase 1b and has potential to dramatically change treatment paradigm by enabling earlier, non-invasive, active treatment for patients with diabetic retinopathy if approved
Lead Product(s): OTT166
Therapeutic Area: Ophthalmology Product Name: OTT166
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
Details:
Proceeds will support the DR-EAM (Diabetic Retinopathy - Early Active Management) Phase 2 study of OTT166 in patients with moderate to severe non-proliferative and mild proliferative diabetic retinopathy. The study is expected to commence early next year.
Lead Product(s): OTT166
Therapeutic Area: Ophthalmology Product Name: OTT166
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
